1x1 Meetings with Stern IR Clients in SF – January 7-10, 2019

Stern IR will be scheduling and hosting meetings for many of our clients around the 2019 J.P. Morgan Healthcare Conference, being held January 7-10th in San Francisco.

This year we’ll be coordinating schedules for around 60 of our top-tier companies, listed here below with brief descriptions. To request specific meetings, please select those companies and fill out the short contact information form with your availability, and a member of our team will follow up shortly for scheduling.

Many of our companies will be hosting meetings in Stern IR suites at The Marker Hotel (501 Geary Street, b/t Jones & Taylor), just 2 blocks away from the conference location at the Westin St. Francis. See you in SF!

Need further assistance?

For any assistance or to schedule over the phone, please contact:

Phone: 212-362-1200
Email: [email protected]

Companies Hosting Meetings

Registration Form

Contact Information

Meeting Time Preferences

Please let us know what dates and times (PT) are best for you. If you are waiting for the 1x1 schedule, please check the box below.

Companies I'm Interested In

Check all that apply.

  • market cap ~$1B

    + more - less

    Clinical-stage biopharma company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Lead product candidate, eptinezumab, is a pivotal-stage mAb that inhibits CGRP. Eptinezumab is currently in late-stage clinical development with a BLA filing planned in 1Q19. If approved, it will be the first-to-market anti-CGRP mAb delivered via infusion. Also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention.

  • market cap ~$225M

    + more - less

    Late-stage biopharmaceutical company developing first-in-class, oral enzyme therapeutics for rare and severe metabolic and kidney disorders. Currently evaluating lead program reloxaliase in URIROX-1, the first of two planned pivotal Phase 3 trials in patients with enteric hyperoxaluria (EH), with topline data expected in 2H19; expect to initiate URIROX-2 by year-end. Allena is also enrolling subjects in Study 206, a Phase 2 basket study of reloxaliase in patients with primary hyperoxaluria or EH and advanced CKD. Second product candidate, ALLN-346, is being developed for hyperuricemia in the setting of advanced CKD. Allena will present proof-of-concept data from animal studies at ACR 2018, and expects to file an IND and initiate Phase 1 clinical studies for ALLN-346 in 2019.

  • market cap ~$150M

    + more - less

    A commercial-stage, UK-based, biopharmaceutical company, leveraging its differentiated, innovative platform technologies to develop ultra-short course allergy immunotherapy vaccines of 4-6 injections (current standard of treatment in the US involves ~100 injections), aimed at enhancing patient compliance, tolerability, and efficacy. The Company’s clinical pipeline focuses on large global markets with late-stage clinical programs including PQ Grass (highly positive Ph2 results announced in May 2018), PQ Birch (Ph3 results expected by end of 2018), and earlier stage assets for the treatment of house dust mites (Ph1 study ongoing) and peanut allergies (leveraging novel VLP platform, in preclinical studies). With annual revenues of ~$100M, Allergy, its subsidiaries and commercial partners, hold a broad portfolio of commercial products in 21 international markets including treatments for grass, tree, ragweed, bee, and wasp allergies.

  • market cap ~$900M

    + more - less

    Raised $117.8M in Nasdaq IPO in June 2018; developing novel small-molecule NMDAr modulators for the treatment of disorders of the brain and nervous system. Aptinyx was spun out of a predecessor company, Naurex, as part of its acquisition by Allergan in 2015. Lead product, NYX-2925, is currently in Phase 2 for Painful Diabetic Peripheral Neuropathy and Fibromyalgia with data expected in 1H19 for both programs. Pipeline also includes NYX-783 in PTSD with Phase 2 data expected in 2H19 and NYX-458 currently entering Phase 1 for Parkinson’s Disease Cognitive Impairment with data excepted in 1H19.

  • market cap ~$2.5B

    + more - less

    Deep pipeline of differentiated antibody-based therapies, built by proprietary technology suite and sustained by accessing novel targets from leading academic labs. FcRn antagonist Efgartigimod (ARGX-113) is currently in 2 ongoing clinical trials in severe autoimmune indications, including a Phase 3 study in myasthenia gravis (MG) and a Phase 2 study in pemphigus vulgaris (PV); recently announced positive Phase 2 data in immune thrombocytopenia (ITP) with plans to advance into a Phase 3 trial; Phase 2 trial in chronic inflammatory demyelinating polyneuropathy (CIDP) expected to initiate in 1H19. Oncology candidate Cusatuzumab (ARGX-110) targets CD70 and is currently in a Phase 1/2 trial (combination therapy) in AML with topline data expected around ASH. Immuno-oncology candidate targeting GARP licensed to AbbVie in September 2018. Broader pipeline includes ARGX-117 against a novel target in the classical pathway of the complement cascade.

  • market cap ~$460M

    + more - less

    Leading the field of targeted protein degradation with its proprietary PROTAC™ platform licensed from Yale University to induce elimination of pathological proteins. Arvinas expects to enter the clinic in 1H19 with its androgen receptor program for patients with castration-resistant prostate cancer, and to enter the clinic in mid-2019 with its estrogen receptor program for patients with ER+ breast cancer. Arvinas is targeting CNS proteins including tau and alpha-synuclein, advancing “undruggable” programs in multiple therapeutic areas, and creating oral and brain-penetrant PROTAC degraders. Arvinas has established discovery deals with Genentech (recently expanded) and Pfizer.

  • market cap ~$20M

    + more - less

    biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) for the treatment of CNS diseases and disorders in areas of urgent high unmet medical need, including brain cancers and neurodegenerative diseases. The fusion of therapeutic molecules to the xB3 platform maximizes brain penetration to create brain penetrant new molecular entities with advantages over BBB technology competitors with demonstrated delivery of large antibodies, small molecules, enzyme replacement therapies and siRNA.

  • market cap ~$20M

    + more - less

    Clinical-stage biotechnology company developing targeted nucleic acid cancer drugs based on proprietary antisense RNAi nanoparticle technology DNAbilize®. Lead candidate prexigebersen, targeting the GBR2 protein, is currently in Phase 2 trials for AML and CML and preclinical studies for solid tumors. An IND is expected to be filed for follow-on candidate BP1002, targeting Bcl2 for lymphoma, this year. Additional product candidate BP1003, targeting Stat3, is in preclinical studies for pancreatic cancer.

  • market cap ~$2.1B

    + more - less

    Global leader in the custom development and manufacture of small molecule active pharmaceutical ingredients (APIs) advanced intermediates, enhanced drug delivery products and finished dosage forms for branded and generic pharmaceuticals with long-standing customer relationships and a history of regulatory excellence. Recent acquisition of Halo Pharmaceuticals expanded Cambrex’s capabilities and customer base as the Company continues to grow its late-stage innovator portfolio to support long-term growth.

  • market cap ~$800M

    + more - less

    Clinical-stage biotech developing and planning to commercialize therapies designed to alleviate pruritus and pain by targeting peripheral kappa opioid receptors (KORs). Lead candidate KORSUVA injection is a first-in-class KOR agonist currently in two Phase 3 efficacy studies in hemodialysis patients with moderate-to-severe CKD-associated pruritus (CKD-aP), with data expected from both trials in 2019. Oral KORSUVA is in a Phase 2 trial in pre-dialysis patients with CKD-aP and a Phase 1 trial in patients with chronic liver disease-associated pruritus (CLD-aP), with a Phase 2 trial expected to start in early 2019. The company also plans to expand Oral KORSUVA into Phase 2 for pruritus associated with certain dermatological conditions in 2019.

  • + more - less

    London-based biotech focused on transforming the treatment of cancer with its next-generation CAR-natural killer T cell (CAR-NKT) platform. Autologous CMD-501 in POC Phase 1 study for neuroblastoma, with interim data expected in 2H19; expecting first patient treated with allogeneic CMD-502 in 1H19. Research collaborations with Baylor College of Medicine and University College London. Completed £60M Series C financing in March 2017.

  • market cap ~$200M

    + more - less

    Biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and CMX521, the first clinical-stage direct-acting antiviral for the treatment and prevention of norovirus.

  • market cap ~175M

    + more - less

    Clinical-stage biopharmaceutical company with lead clinical programs including: EZH2 inhibitor CPI-1205, in two ongoing Phase 1b/2 trials in castration-resistant prostate cancer (PRoSTAR) and as a combination therapy in solid tumors (ORIOn-E); and CPI-0610, a potential best-in-class BET inhibitor, in a Phase 2 trial in myelofibrosis (MANIFEST). Both lead programs are expected to deliver proof-of-concept data in mid-2019, with potentially superior next-gen EZH2 inhibitor CPI-0209 expected to enter the clinic in 2019.

  • market cap ~$160M

    + more - less

    ContraFect is a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases. The Company’s lead product candidate, exebacase (CF-301), is currently in a Phase 2 clinical trial for the treatment of Staphylococcus aureus (Staph aureus) bacteremia, including endocarditis and is the first lysin from its lysin platform to enter clinical studies in the U.S.

  • market cap ~$1.2B

    + more - less

    As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

  • + more - less

    Treating neurodegenerative diseases through a novel focus on inflammation-induced synaptic dysfunction. Lead program, neflamapimod, is the most advanced oral drug targeting synaptic dysfunction in Alzheimer’s disease. Reported positive Phase 2a clinical data and are in an ongoing Phase 2b proof-of-concept clinical study in patients in the early stages of Alzheimer's with demonstrated memory impairment. The phase 2b study is projected to be fully enrolled in early 2019, with data expected in 2H19. Neflamapimod has broad potential with Phase 2 studies in Huntington’s disease and dementia of Lewy bodies planned for 2019.

  • market cap ~$1.3B

    + more - less

    Developing targeted therapies for cancer and companion imaging agents. Phase 3 (VISION) trial of lead candidate 177Lu-PSMA-617, a radioligand therapeutic (RLT) that targets the prostate-specific membrane antigen (PSMA), has two alternative primary endpoints, rPFS and OS, with either sufficient for full approval and the first rPFS analysis for potential approval expected in 2H19. CAR-T cell bi-specific adaptor molecule platform being developed in collaboration with Seattle Children's Research Institute.

  • + more - less

    Developing novel and safe T-cell therapies with a focus on solid tumors and overcoming limitations of current therapies such as cytokine release syndrome (CRS) and drug-related neurotoxicity. The company has developed two proprietary platforms: ARTEMISTM T-cell receptor platform and E-ALPHA® antibody discovery platform. Current pipeline includes candidates ET140202, ET190L1 ARTEMIS and ET019002, for Hepatocellular Carcinoma, Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia, respectively. Recently announced positive proof-of-concept first-in-human data, including a complete response, from ongoing ET140202 China study of AFP-positive patients with HCC at the CAR-TCR Summit in September.

  • market cap ~$350M

    + more - less

    Clinical-stage biopharmaceutical company developing a new modality of medicine, monoclonal microbials, designed to act on the gut-body network for the treatment of many different diseases, including immunoinflammatory, cancer, autoimmune, metabolic, neurological and neuroinflammatory conditions. Currently advancing three product candidates -- EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer -- for which ten clinical readouts are expected during 2019 and 2020.

  • market cap ~$1B

    + more - less

    A clinical-stage company dedicated to the development of first-in-class, cell-based immunotherapies for cancer and immune disorders, including universal, off-the-shelf NK cell and CAR T-cell product candidates derived from master induced pluripotent stem cell (iPSC) lines. The Company has developed a deep pipeline of universal, off-the-shelf cell products, including FT500 (iPSC-derived NK cell for use in combination with checkpoint inhibitor therapy), FT516 (iPSC-derived, high-affinity non-cleavable CD16 NK cell for use in combination with monoclonal antibody therapy), FT538 (iPSC-derived, high-affinity non-cleavable CD16, CD38-null NK cell for use in combination with daratumumab) and FT819 (iPSC-derived, TCR-null, CAR19 T cell). FATE recently announced submission to the FDA of an IND application for FT500, and expects to initiate first-in-human clinical trials of several product candidates emerging from its iPSC product platform in 2019. In addition, FATE recently announced a strategic collaboration with ONO Pharmaceutical to co-develop two iPSC-derived CAR T-cell cancer immunotherapies. FATE is also conducting three clinical trials of FATE-NK100, a donor-derived, adaptive memory NK cell cancer immunotherapy, for the treatment of AML, ovarian cancer and advanced solid tumors; and a Phase 2 clinical trial of ProTmune, a next-generation allogeneic graft for the prevention of acute GvHD.

  • + more - less

    Clinical-stage biopharmaceutical company leveraging its big data and machine learning approach to identify novel therapeutic targets that regulate the immune response to disease and identify biomarkers for patient selection. FLX is focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders. FLX Bio’s lead compound FLX475 is a best-in-class oral, small molecule antagonist of CCR4 that selectively blocks the recruitment of regulatory T cells to the tumor site without removing affecting beneficial cells. FLX Bio is conducting a Phase 1/2 open-label clinical study of FLX475 in selected cancers to evaluate the safety and efficacy of monotherapy and in combination with anti-PD1 antibodies, with proof-of-concept data expected by the end of 2019. FLX’s second oral CCR4 antagonist, FLX193, targets allergic disorders including atopic dermatitis and asthma, and is expected to enter clinical studies in mid-2019 with Phase 2 efficacy data in atopic dermatitis patients anticipated in 1H 2020. FLX is funded by leading investors, including The Column Group (TCG), Kleiner Perkins (KP), Topspin Partners, GV and Celgene Corporation, and has assembled a leadership team and advisory group with a proven track record of success and team of scientists.

  • market cap ~$425M

    + more - less

    Clinical-stage immuno-oncology company developing novel checkpoint therapies to activate macrophages in the fight against cancer. Lead program 5F9, a monoclonal antibody against CD47, has demonstrated clinical activity as a monotherapy and combination agent; six trials are currently ongoing in patients with solid tumors, acute myeloid leukemia, non-Hodgkin’s lymphoma, ovarian cancer and colorectal carcinoma, with multiple data readouts expected in 2019.

  • + more - less

    Generation Bio is a biotechnology company developing a proprietary and highly disruptive gene therapy platform, closed-ended DNA (ceDNA). ceDNA vectors have drug-like properties, AAV-like durability, and can be titrated, re-dosed and manufactured using a non-viral biologics process. The Company is led by an experienced management team and has raised $115M from Atlas, Fidelity, Invus, Deerfield and others.

  • + more - less

    Company focused on developing and commercializing small-molecule kinase inhibitor therapeutics for the safe and effective treatment of neurodegeneration inside and outside of the brain. Their lead small-molecule product candidate, IkT-148009, is an Abl kinase inhibitor that targets underlying disease mechanisms to reverse the course of Parkinson’s disease and the GI complications of Parkinson’s disease.

  • + more - less

    ICT is a biotechnology company developing cellular immunotherapies for the treatment of cancer. The Company’s proprietary series of CAR-T candidates has achieved promising preclinical and clinical results, including lead candidate ICTCAR014, targeting CD19 + PD1 for the treatment of Non-Hodgkin Lymphoma. ICT also has a broad pipeline of additional CAR-T candidates targeting other blood and liquid cancers and solid tumors.

  • market cap ~$3B

    + more - less

    Leader in progressive non-viral liver diseases. Strong global launch of OCALIVA® (OCA), the first new therapy for primary biliary cholangitis (PBC) in 20 years. Significant market opportunity with leading nonalcoholic steatohepatitis (NASH) development program, supported by robust safety and efficacy data and Breakthrough Therapy designation, with top-line data from the Phase 3 REGENERATE trial expected in 1H19.

  • + more - less

    Biopharmaceutical company discovering and developing therapies that modulate novel targets in the innate immune system as next-generation treatments for cancer, autoimmunity and inflammatory disorders. In July 2018, launched subsidiary, IFM Tre, to develop suite of chemically distinct small molecule NLRP3 antagonists for inflammatory disease. IFM Tre’s pipeline includes systemic, gut-directed and CNS-penetrant drug candidates; lead systemic candidate is expected to enter Phase 1 trials in healthy volunteers in 2019. IFM spun out of IFM Therapeutics, Inc., prior to $2.3B sale of oncology assets to Bristol-Myers Squibb in 2017.

  • market cap ~$135M

    + more - less

    Developing IPI-549, a first-in-class, potent, oral, and selective PI3K-γ inhibitor, with transformative potential in immuno-oncology. Robust ongoing Phase 1b study in ~ 200 patients has demonstrated that IPI-549 is well-tolerated, on-mechanism and clinically active as a monotherapy as well as in combination with Opdivo, the latter in a clinical collaboration with BMS. Infinity also has an ongoing clinical collaboration with Arcus Biosciences investigating two triple combinations including IPI-549 with Arcus’ dual adenosine receptor antagonist, AB928, anti-PD-1 antibody, AB122, and chemotherapy in triple negative breast cancer and ovarian cancer.

  • market cap ~$200M

    + more - less

    Developing drugs based on its proprietary Accordion Pill (AP) platform technology, an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company's lead product is Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, a late stage Phase 3 asset being developed for advanced Parkinson's disease patients, with data expected mid-2019. Pipeline also includes AP-cannabinoids, an Accordion Pill to deliver either or both of the primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC) for various indications including low back neuropathic pain and fibromyalgia.

  • + more - less

    Clinical-stage biotechnology company pioneering a new immune-based approach to treating cancer based on proprietary DfuseRxSM technology platform. The technology which identifies novel drug formulations that combine cell penetration enhancers with anti-cancer agents. Products, which are directly injected into tumors, diffuse through tumors, kill the cancer cells and elicit an adaptive immune response. Lead candidate, INT230-6, is a fixed-ratio combination of cisplatin, vinblastine, and an amphiphilic cell penetration enhancer molecule currently being evaluated in a Phase 1/2 dose-escalation study for the treatment of several types of refractory superficial and deep cancers, including melanoma, head and neck, lymphoma, breast, pancreatic, colon, liver, and lung. Combinations with anti-PD1 checkpoint inhibitors are also planned. Clinical data presented at the 2018 ESMO conference demonstrated use of INT230-6 regressed injected tumors and an abscopal effect was observed in untreated metastases.

  • market cap ~$1B

    + more - less

    Developing cancer immunotherapies for the treatment of various cancers using its tumor infiltrating lymphocyte (TIL) technology and through robust manufacturing partnerships and collaborations throughout the U.S. and EU. Lead product candidate, lifileucel (LN-144), which has received both Orphan Drug and Fast Track Designations, is currently in Phase 2 for the treatment of patients with metastatic melanoma with additional Phase 2 programs for LN-145 for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck, recurrent, metastatic or persistent cervical cancer (Orphan Drug Designation) and locally advanced or metastatic non-small cell lung cancer in addition to a basket study of several tumor types. Additional pipeline of TIL combination trials for the treatment of melanoma, ocular melanoma, ovarian cancer, sarcomas, pancreatic cancer and non-small cell lung cancer.

  • + more - less

    Privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies. The Company is advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase I trial in early 2019. A second program for its human ADCC-enabling anti-TIGIT antibody (EOS884448) is expected to enter the clinic in 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain) in 2011. In June 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, alongside new investors HBM Partners, 6 Dimensions Capital and Curative Ventures.

  • market cap ~$215M

    + more - less

    Clinical stage immunotherapy company using its Translational Science Platform to focus on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right immunotherapy to the right patient. Lead product candidate, JTX-2011 is an agonist monoclonal antibody that binds to and activates ICOS, is currently in Phase 1/2. In addition, Jounce has a robust discovery pipeline of programs targeting additional adaptive immune cells such as B cells and T regulatory cells, macrophages and stromal cells plus its ongoing collaboration with Celgene.

  • market cap ~$300M

    + more - less

    Developing and commercializing therapeutics using its proprietary AMPPLIFY TM mucus penetrating particle technology. Commercial launch of INVELTYSTM (KPI-121 1.0%) is expected in early 2019. INVELTYS is the first approved BID steroid for treatment of inflammation and pain following ocular surgery, and has a class leading combination of efficacy, safety and dosing. The Company expects annual peak sales to be above $300M. Lead candidate KPI-121 0.25% for temporary relief of dry eye disease has completed one Phase 2 and two Phase 3 studies (STRIDE 1 and STRIDE 2), with an NDA filing based on current data package expected in 2H18, and topline Phase 3 (STRIDE 3) data is expected in 2019. Recent financings provide runway through NDA filing of KPI-121 0.25%, INVELTYS launch, and topline results for the STRIDE 3 trial of KPI-121 0.25%.

  • market cap ~$300M

    + more - less

    Genome editing company focused on developing medicines to durably treat rare diseases using its proprietary platform, GeneRide. GeneRide harnesses homologous recombination to precisely integrate corrective genes into a patient’s genome, leveraging endogenous promoters to provide a stable therapeutic effect. Logic expects to move its lead product candidate, LB-001, into the clinic in 2019 for the treatment of Methylmalonic Acidemia, or MMA, a life-threatening disease that presents at birth. Broad pipeline of preclinical candidates with demonstrated proof of concept in hemophilia B, alpha-1-antitrypsin deficiency, or A1ATD, and Crigler-Najjar syndrome animal disease models. Successful IPO completed in October 2018 raising $81M

  • market cap ~$200M

    + more - less

    Clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Product candidate XMT-1522 in Phase 1 clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. Product candidate, XMT-1536, is in Phase 1 clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.

  • + more - less

    Clinical-stage company developing first-in-class, small-molecule NAD+ enhancers, initially targeting rare mitochondrial diseases. NAD+ levels have been shown to decline as humans age and modulating NAD+ to preserve health and normal metabolism is believed to have broad therapeutic potential. Lead candidate, MIB-626, is a proprietary, crystallized form of an NAD+ precursor, currently being evaluated in a Phase 1b, multiple-dose clinical trial; additional preclinical studies are ongoing in parallel to support INDs for Phase 2 trials in Frederich’s Ataxia and an undisclosed rare mitochondrial disease, expected in 2019. Robust R&D engine, with a library of ~100 early-stage, next-generation analogs with tissue-specific NAD+ increasing properties. Backed by the Keystone Group (Robert Bass) and supported by a team of leading scientists, including David Sinclair (Harvard), Anthony Sauve (Weill Cornell), Rajendra Apte (WashU) and Carlos Bustamante (Stanford).

  • + more - less

    Leading orphan endocrine disease company with livoletide, a pivotal-stage asset for Prader-Willi syndrome, and nevanimibe, in a Phase 2 trial for congenital adrenal hyperplasia. Expected to be publicly trading under the ticker MLND in November 2018.

  • market cap ~$1B

    + more - less

    Biotechnology company leveraging a validated innovative scientific platform to discover and develop novel therapeutics purposefully designed to treat rare, immune-mediated diseases. Pipeline includes M281, a potentially best-in-class anti-FcRn antibody, expected to initiate Phase 2 studies in Myasthenia Gravis (MG) and Hemolytic Disease of the Fetus and Newborn (HDFN) in 4Q18; M254, a hyper-sialylated human immunoglobulin (hsIgG) designed as a high potency alternative for intravenous immunoglobulin (IVIg); and M230 (CSL730), a potential first-in-class novel recombinant Fc multimer being developed in collaboration with CSL. Momenta also has a focused biosimilar pipeline of two candidates in development including M923 (b-HUMIRA®) and M710 (b-EYLEA®). Momenta’s two FDA-approved complex generic products, enoxaparin sodium injection and Glatopa® (glatiramer acetate injection), are marketed by its collaboration partner, Sandoz.

  • market cap ~$2.1B

    + more - less

    Clinical-stage biopharmaceutical company pioneering precision medicine approach to discover, develop and commercialize targeted therapies for rare cardiovascular diseases. Lead product candidate, mavacamten, is currently in a pivotal Phase 3 trial for symptomatic, obstructive hypertrophic cardiomyopathy (HCM), EXPLORER-HCM, with data expected in 2H20. Mavacamten is also being evaluated in the open label extension portion of the Phase 2 PIONEER-HCM trial and in a Phase 2 trial for non-obstructive HCM, with data expected in 1Q19 and 2H19, respectively. Broader pipeline includes MYK-491, in Phase 1b for dilatated cardiomyopathy, in addition to multiple research-stage programs.

  • market cap ~$300M

    + more - less

    Clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Neon is using its neoantigen platform to develop both vaccine and T cell therapies, including NEO-PV-01, a clinical stage neoantigen vaccine for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of a subset of estrogen-receptor-positive breast cancer.

  • market cap ~$120M

    + more - less

    Commercial-stage pharma company, develops, manufactures and commercializes products utilizing its proprietary drug-delivery technology. Three marketed branded products for ADHD: Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets, Cotempla XR-ODT™ (methylphenidate) extended-release orally disintegrating tablets, and Adzenys ER™ (amphetamine) extended-release oral suspension. Plans to enter nausea and vomiting program into the clinic in 4Q18 and build pipeline and expand commercial portfolio.

  • market cap ~$100M

    + more - less

    Clinical-stage biopharmaceutical company developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer using its immunotherapy platform, TAVO (tavokinogene telseplasmid) which enables the intratumoral delivery of DNA-based interleukin-12 by employing electroporation to produce a controlled, localized expression of IL-12 in the tumor microenvironment. Pipeline includes TAVO in combination with pembrolizumab for the treatment of melanoma and TAVO monotherapy for triple negative breast cancer.

  • + more - less

    Leading precision medicine company providing advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. Personalis’ ACE Technology forms the foundation of all its products; ACE is designed to obtain the most comprehensive and accurate tumor molecular profile, and to improve every step in the next-generation sequencing process, from nucleic acid extraction, to sequencing assays, to data analytics. This genomic data is shared with biopharmaceutical companies to drive their immuno-oncology clinical and biomarker discovery program, enabling the rational design and development of effective cancer immunotherapies.

  • + more - less

    Cambridge-based biotech revolutionizing the paradigm of small molecule drug discovery through its protein-motion focused platform. The Relay Tx platform integrates experimental and computational techniques to elucidate novel hypotheses for disease modification and accelerate the rational design of small molecules. Relay has two programs that entered into IND-enabling studies in late 2018 with a rich pipeline of additional programs poised to enter development in the coming two years. Relay has initially focused in oncology, but the platform is widely applicable to a range of therapeutic areas and diseases. $120M raised to-date; investors include Third Rock Ventures, BVF Partners, Casdin Capital, Section 32, D.E. Shaw Research, EcoR1, Alexandria and GV.

  • market cap ~$400M

    + more - less

    Clinical-stage biopharmaceutical company focused on the development of selective TORC1 inhibitors to treat aging-related diseases. Reported positive results for lead candidate, RTB101 in a Phase 2b trial to enhance immune function and reduce the incidence of respiratory tract infections in the high-risk elderly, and will initiate a pivotal Phase 3 program in the first half of 2019. TORC1 inhibition has shown the potential to ameliorate several aging-related diseases, and resTORbio plans to initiate a Phase 2 study in Parkinson’s Disease in 4Q18 / 1Q19. Well capitalized through 2020 as of June 30, 2018.

  • market cap ~$1B

    + more - less

    Biopharmaceutical company developing and commercializing therapeutics to transform the care of people living with rare genetic disorders of obesity. Lead product candidate setmelanotide has demonstrated proof-of-concept in POMC and LEPR deficiency obesities, Bardet-Biedl Syndrome (BBS) and Alström Syndrome, driving significant reductions in both weight and hunger. Pivotal Phase 3 trials in POMC and LEPR are fully enrolled, with initial data expected in 3Q19; combined pivotal Phase 3 trial in BBS and Alström Syndrome is expected to initiate by year-end. Initial preliminary signs of efficacy have also been observed in MC4R pathway heterozygous deficiency obesities and POMC epigenetic disorders. Setmelanotide has been granted both Breakthrough Therapy and PRIME Designations, which include POMC, LEPR, BBS and Alström Syndrome.

  • market cap ~$6B

    + more - less

    Sage is a clinical-stage biopharmaceutical company advancing a portfolio of novel product candidates targeting critical CNS receptor systems. Lead product candidate, ZULRESSO™ (brexanolone injection), completed Phase 3 clinical development for postpartum depression (PPD) and an NDA is currently under review by the FDA. The Company’s second product candidate, SAGE-217, is in Phase 3 development for major depressive disorder and PPD.

  • market cap ~$500M

    + more - less

    Proprietary platform targeting growth factor signaling in the disease microenvironment with pipeline focused on neuromuscular disorders, cancer, fibrosis and anemia. Lead product candidate, SRK-015, is a highly selective inhibitor of myostatin currently in Phase 1 trials. The company plans to initiate Phase 2 POC trial in 1Q19 to improve muscle strength and motor function in later-onset Spinal Muscular Atrophy (SMA) patients, as a monotherapy or in conjunction with a SMN upregulator. In addition to other assets in the pipeline, the company plans to nominate a product candidate and first indication in its TGFb1 program in either immuno-oncology or fibrosis in 1H19.

  • + more - less

    Leading healthcare company revolutionizing drug discovery through advanced computational methods, molecular simulations and enterprise software solutions that accelerate and increase the efficiency of drug discovery. Schrödinger has a growing pipeline of early stage assets, deep partnerships and collaborations with biotechnology and pharmaceutical companies to deliver development candidates, and is a cofounder of leading biotech companies including Nimbus Therapeutics (whose ACC program was acquired by Gilead for $1.2B), Morphic Therapeutic, and others.

  • market cap ~$300M

    + more - less

    Unlocking the full potential of biologic therapies for the treatment of rare and serious diseases using its proprietary, ImmTOR™ technology. Pipeline includes lead product candidate, SEL-212, for the treatment of severe gout and the associated debilitating symptoms, including flares and gouty arthritis, SEL-403 for the treatment of malignant pleural or peritoneal mesothelioma and proprietary gene therapy products for rare inborn errors of metabolism, which have the potential to enable repeat administration.

  • market cap ~$30M

    + more - less

    Late-stage biotech focused on novel cancer immunotherapeutics for a broad range of indications. Lead product candidate galinpepimut-S (GPS) is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein. GPS is Phase 3-ready for AML and malignant pleural mesothelioma, in Phase 2 trials for multiple myeloma and ovarian cancer, and in a Phase 1/2 basket study with pembrolizumab. Second product candidate nelipepimut-S (NeuVax™) has demonstrated positive Phase 2b results in combination with Herceptin© in triple negative breast cancer patients, with data being presented at ESMO and SITC 2018 meetings.

  • + more - less

    Developing first-in-class cancer immunotherapies that generate effective anti-tumor immunity, using a proprietary drug discovery platform called SPIRIT coupled with a precision medicine approach for patient selection. The lead candidate SNS-301 is a cancer vaccine that targets ASPH, a tumor-specific antigen (TSA), advancing into phase 2 studies in high unmet need indications including solid tumors and hematological malignancies as both monotherapy and combination therapy with checkpoint inhibitors. A cell therapy program (SNS-723) targeting ASPH is planned to begin Phase 1 in 2019 in solid tumors and additional target discovery and pre-clinical validation is ongoing.

  • market cap ~$300M

    + more - less

    Microbiome company developing pipeline of novel Ecobiotic® medicines to treat disease by restoring the function of a dysbiotic or unhealthy microbiome. Lead Phase 3 product candidate SER-109 has Breakthrough and Orphan designation for multiply-recurrent C. difficile infection. Pipeline includes SER-287, which in a Phase 1b study demonstrated an improvement in clinical remission rate and endoscopic improvement in patients with ulcerative colitis, and SER-401, which is being developed to improve outcomes in individuals being treated with immune-oncology treatments.

  • market cap ~$184M

    + more - less

    A multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections. The company’s lead candidate, SPR994, an oral carbapenem, is expected to enter a pivotal Phase 3 clinical trial around year-end 2018 for the treatment of complicated urinary tract infections (cUTIs). Pipeline includes its Potentiator Platform, SPR741 and SPR206, to treat MDR Gram-negative infections in the hospital setting and SPR720, a novel oral therapy candidate for the treatment of pulmonary non-tuberculous mycobacterial (NTM) infection.

  • market cap ~$280M

    + more - less

    Clinical-stage company pioneering the development of a novel class of living medicines. Leveraging a proprietary drug development platform that applies synthetic biology to genetically engineer probiotic microbes, which can act from the gut to carry out critical functions missing or damaged due to disease. Lead programs are initially focused on rare metabolic diseases: SYNB1020, in development to treat hyperammonemia, is currently being evaluated in an ongoing Phase 1b/2a study in patients with cirrhosis and elevated ammonia, expected to report topline data by YE 2018; and SYNB1618, in development for the treatment of PKU, is currently being evaluated in patients in an ongoing Phase 1/2a study, expected to report topline data in mid-2019. Preclinical development efforts ongoing for Synthetic Biotic™ medicines to treat more common diseases, including liver disease, inflammatory and immune disorders, and cancer; expected to advance first IO candidate into IND-enabling studies by YE 2018.

  • market cap ~$260M

    + more - less

    Clinical-stage biopharmaceutical company pioneering the understanding of the non-coding region of the genome to advance medicines that control the expression of genes. Lead product candidates include SY-1425, a selective RARα agonist in a Phase 2 clinical trial for genomically defined subsets of patients with AML and MDS, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial for patients with advanced solid tumors; plan to announce initial clinical data from combination cohorts in Phase 2 SY-1425 trial and dose escalation portion of Phase 1 SY-1365 trial in 4Q18. Broader pipeline includes multiple discovery-stage programs for cancer, including immuno-oncology, and genetic disease.

  • market cap ~$300M

    + more - less

    Developing immunotherapy products using proprietary, novel T cell technologies to address a wide range of hematologic and solid tumor types. Clinical pipeline currently includes three programs — Lymphoma, Multiple Myeloma and HER2+ cancers — based on the Company’s Antibody Coupled T Cell Receptor (‘ACTR') technology platform.

  • market cap ~$30M

    + more - less

    A clinical-stage biotechnology company focused on developing oral recombinant protein vaccines based on its VAASTTM oral vaccine delivery platform. All vaccines are administered by tablet and are designed to generate both systemic and mucosal immune responses, the optimal approach to protect against mucosal pathogens such as norovirus, flu and RSV. Phase 2 Challenge and Phase 1b bivalent studies in the norovirus tablet vaccine are scheduled to start in 4Q18. Other programs in the pipeline target seasonal influenza, RSV and a therapeutic vaccine for HPV.

  • market cap ~$100M

    + more - less

    Med tech company focused on women’s intimate health with internationally patented Viveve® System delivering CMRF technology in a single in-office session. International regulatory approvals and clearances received for vaginal laxity and/or improvement in sexual function in 50+ countries. VIVEVE II study underway to evaluate the safety and efficacy of the Viveve System for the improvement of sexual function in women following vaginal childbirth under FDA approved IDE. LIBERATE-International trial in process and IDE in review to conduct LIBERATE-U.S. trial. Both LIBERATE registration trials will evaluate the safety and efficacy of the Viveve System for the treatment of stress urinary incontinence, which could lead to regulatory approvals in these indications.

  • market cap ~$2B

    + more - less

    Clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer using proprietary XmAb® technology. Currently, 12 candidates engineered with XmAb technology are in clinical development internally and with partners. Internal programs include XmAb®5871, expected to enter Phase 3 trial in IgG4-RD by YE 2018, in addition to a growing pipeline of bispecific antibodies for oncology indications, including a suite of tumor microenvironment activators. Expect to report topline Phase 1 data for bispecific XmAb®14045 in AML by YE 2018; for XmAb®13676 in B-cell malignancies and for XmAb®18087 in NET/GIST in 2019.

Sending ...